FR15C0048I1 - Anticorps antagonistes de il-17 - Google Patents

Anticorps antagonistes de il-17

Info

Publication number: FR15C0048I1
Authority: FR; France
Prior art keywords: antagonist antibodies; antagonist; antibodies
Prior art date: 2004-08-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

NOVARTIS PHARMA GmbH

Novartis AG

Original Assignee

NOVARTIS PHARMA GmbH

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-05

Filing date

2015-07-03

Publication date

2015-08-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32982602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR15C0048(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-07-03 Application filed by NOVARTIS PHARMA GmbH, Novartis AG filed Critical NOVARTIS PHARMA GmbH

2015-08-28 Publication of FR15C0048I1 publication Critical patent/FR15C0048I1/fr

2015-11-20 Application granted granted Critical

2015-11-20 Publication of FR15C0048I2 publication Critical patent/FR15C0048I2/fr

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Orthopedic Medicine & Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Pain & Pain Management (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Dermatology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

FR15C0048C 2004-08-05 2015-07-03 Anticorps antagonistes de il-17 Active FR15C0048I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0417487.6A GB0417487D0 (en)	2004-08-05	2004-08-05	Organic compound
PCT/EP2005/008470 WO2006013107A1 (fr)	2004-08-05	2005-08-04	Anticorps antagonistes de il-17

Publications (2)

Publication Number	Publication Date
FR15C0048I1 true FR15C0048I1 (fr)	2015-08-28
FR15C0048I2 FR15C0048I2 (fr)	2015-11-20

Family

ID=32982602

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR15C0048C Active FR15C0048I2 (fr)	2004-08-05	2015-07-03	Anticorps antagonistes de il-17

Country Status (40)

Country	Link
US (8)	US7807155B2 (fr)
EP (5)	EP2902039B1 (fr)
JP (1)	JP4682200B2 (fr)
KR (2)	KR100852523B1 (fr)
CN (1)	CN101001645B (fr)
AR (1)	AR050200A1 (fr)
AT (1)	ATE517924T1 (fr)
AU (2)	AU2005268857C1 (fr)
BE (1)	BE2015C041I2 (fr)
BR (3)	BR122018075556B1 (fr)
CA (1)	CA2573586C (fr)
CY (6)	CY1111963T1 (fr)
DK (4)	DK2366405T3 (fr)
EC (1)	ECSP077198A (fr)
ES (4)	ES2536228T3 (fr)
FR (1)	FR15C0048I2 (fr)
GB (1)	GB0417487D0 (fr)
HK (3)	HK1101277A1 (fr)
HR (3)	HRP20110758T4 (fr)
HU (4)	HUE025815T2 (fr)
IL (1)	IL180717A (fr)
LT (3)	LT2902039T (fr)
LU (2)	LU92768I2 (fr)
MA (1)	MA28982B1 (fr)
MX (1)	MX2007001338A (fr)
MY (1)	MY144925A (fr)
NL (1)	NL300749I2 (fr)
NO (9)	NO336279B1 (fr)
NZ (1)	NZ552658A (fr)
PE (1)	PE20060418A1 (fr)
PL (4)	PL2902039T3 (fr)
PT (4)	PT2364729E (fr)
RU (2)	RU2426741C3 (fr)
SG (1)	SG155186A1 (fr)
SI (4)	SI2902039T1 (fr)
TN (1)	TNSN07034A1 (fr)
TR (1)	TR201808057T4 (fr)
TW (1)	TWI359153B (fr)
WO (1)	WO2006013107A1 (fr)
ZA (1)	ZA200700242B (fr)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
GB0417487D0 (en) *	2004-08-05	2004-09-08	Novartis Ag	Organic compound
GB0425569D0 (en)	2004-11-19	2004-12-22	Celltech R&D Ltd	Biological products
DE602006009834D1 (de)	2005-09-01	2009-11-26	Schering Corp	Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
DK1963368T6 (da)	2005-12-13	2020-06-29	Lilly Co Eli	Anti-il-17-antistoffer
SG170749A1 (en)	2005-12-20	2011-05-30	Sbi Biotech Co Ltd	Anti-ilt7 antibody
AR060017A1 (es)	2006-01-13	2008-05-21	Novartis Ag	Composiciones y metodos de uso para anticuerpos de dickkopf -1
AU2007235199B8 (en) *	2006-01-31	2010-10-28	Novartis Ag	IL-17 antagonistic antibodies for treating cancer
US7910703B2 (en)	2006-03-10	2011-03-22	Zymogenetics, Inc.	Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
EP2044118A2 (fr)	2006-06-13	2009-04-08	Zymogenetics, Inc.	Antagonistes d'il-17 et d'il-23 et leurs procédés d'utilisation
TW200815469A (en) *	2006-06-23	2008-04-01	Astrazeneca Ab	Compounds
GB0612928D0 (en)	2006-06-29	2006-08-09	Ucb Sa	Biological products
AR063683A1 (es)	2006-08-11	2009-02-11	Schering Corp	Anticuerpos para il-17a
GB0620729D0 (en)	2006-10-18	2006-11-29	Ucb Sa	Biological products
TWI426918B (zh)	2007-02-12	2014-02-21	Merck Sharp & Dohme	Ｉｌ-２３拮抗劑於治療感染之用途
EP2425838A3 (fr)	2007-02-28	2012-05-02	Schering Corporation	Polythérapie pour le traitement de maladies immunes
EP2468302A1 (fr)	2007-05-29	2012-06-27	Novartis AG	Nouvelles indications pour une thérapie anti-IL-1-bêta
WO2008156865A2 (fr) *	2007-06-20	2008-12-24	Schering Corporation	Biomarqueurs de destruction d'articulation pour une thérapie anti-il-17a d'une maladie inflammatoire des articulations
ES2614735T3 (es) *	2007-07-23	2017-06-01	Janssen Biotech, Inc.	Métodos y composiciones para tratar los trastornos relacionados con fibrosis usando antagonistas de la IL-17
WO2009033091A1 (fr) *	2007-09-06	2009-03-12	City Of Hope	Traitement d'une maladie auto-immune médiée par th17 par l'intermédiaire de l'inhibition de stat3
KR101616995B1 (ko) *	2007-12-03	2016-06-07	(주)아모레퍼시픽	슬리밍용 조성물
WO2009082624A2 (fr) *	2007-12-10	2009-07-02	Zymogenetics, Inc.	Antagonistes de il-17a, il-17f et il-23 et procédés d'utilisation de ceux-ci
US9309313B2 (en) *	2008-01-09	2016-04-12	The Schepens Eye Research Institute, Inc.	Therapeutic compositions for treatment of ocular inflammatory disorders
GB0807413D0 (en)	2008-04-23	2008-05-28	Ucb Pharma Sa	Biological products
CN102076355B (zh)	2008-04-29	2014-05-07	Abbvie公司	双重可变结构域免疫球蛋白及其用途
JP5771140B2 (ja) *	2008-04-29	2015-08-26	アムゲンリサーチ（ミュンヘン）ゲーエムベーハー	治療用のｇｍ−ｃｓｆおよびｉｌ−１７阻害剤
WO2009136286A2 (fr)	2008-05-05	2009-11-12	Novimmune Sa	Anticorps à réaction croisée anti-il-17a/il-17f et leurs procédés d'utilisation
NZ589434A (en)	2008-06-03	2012-11-30	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
CN102112494A (zh)	2008-06-03	2011-06-29	雅培制药有限公司	双重可变结构域免疫球蛋白及其用途
US8822645B2 (en)	2008-07-08	2014-09-02	Abbvie Inc.	Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
EP2331575B1 (fr) *	2008-09-29	2014-05-28	Roche Glycart AG	Anticorps contre IL17 humain et usages correspondants
WO2010102251A2 (fr)	2009-03-05	2010-09-10	Abbott Laboratories	Protéines de liaison à il-17
CN102753578B (zh) *	2009-04-27	2015-04-22	诺华股份有限公司	增加肌肉生长的组合物和方法
CA2759848C (fr)	2009-05-05	2018-12-04	Novimmune S.A.	Anticorps anti-il-17f et leurs methodes d'utilisation
AU2010289527C1 (en)	2009-09-01	2014-10-30	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
EA201270528A1 (ru) *	2009-10-10	2012-12-28	Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити	Композиции цитокинов семейства il-17 и их применение
KR20140015139A (ko)	2009-10-15	2014-02-06	애브비 인코포레이티드	이원 가변 도메인 면역글로불린 및 이의 용도
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
EA029283B1 (ru)	2009-10-30	2018-03-30	Янссен Байотек, Инк.	Антагонисты il-17a
NZ603570A (en)	2010-05-20	2014-12-24	Ablynx Nv	Biological materials related to her3
RU2013109275A (ru)	2010-08-03	2014-09-10	Эббви Инк.	Иммуноглобулины с двумя вариабельными доменами и их применение
BR112013002831A2 (pt)	2010-08-05	2016-11-01	Anaptysbio Inc	anticorpos direcionados contra a il-17
US8822663B2 (en)	2010-08-06	2014-09-02	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
CA2809433A1 (fr)	2010-08-26	2012-03-01	Abbvie Inc.	Immunoglobulines a deux domaines variables et leurs utilisations
MX2013003681A (es)	2010-10-01	2013-11-20	Moderna Therapeutics Inc	Ácidos nucleicos manipulados y métodos de uso de los mismos.
NO2625199T3 (fr)	2010-10-08	2018-04-21
TR201909531T4 (tr) *	2010-11-05	2019-07-22	Novartis Ag	Anti-il-17 anti̇korlari kullanilarak anki̇lozan spondi̇li̇t tedavi̇ etme yöntemleri̇
AU2014259523B2 (en) *	2010-11-05	2016-02-04	Novartis Ag	Methods of treating psoriatic arthritis using IL-17 antagonists
WO2012082573A1 (fr)	2010-12-13	2012-06-21	Novartis Ag	Procédés prédictifs et procédés de traitement de l'arthrite en utilisant des antagonistes de l'il-17
GB201100282D0 (en)	2011-01-07	2011-02-23	Ucb Pharma Sa	Biological methods
US10208349B2 (en)	2011-01-07	2019-02-19	Ucb Biopharma Sprl	Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
JP5947041B2 (ja) *	2011-01-07	2016-07-06	第一三共ヘルスケア株式会社	安全なｉｌ−１７産生抑制剤
WO2012095507A1 (fr) *	2011-01-13	2012-07-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthodes et trousses permettant de prédire le risque de survenue d'un événement cardiovasculaire chez un sujet
MX341489B (es)	2011-01-14	2016-08-23	Ucb Pharma Sa	Moleculas de anticuerpo que se unen a interleucina 17a (il-17a) e interleucina 17f (il-17f).
WO2012125680A1 (fr)	2011-03-16	2012-09-20	Novartis Ag	Méthodes de traitement de vascularite à l'aide d'un molécule de liaison à l'il-17
CN107915769A (zh) *	2011-03-29	2018-04-17	葛兰素史密斯克莱有限责任公司	用于蛋白纯化的缓冲液体系
JP2014511687A (ja)	2011-03-31	2014-05-19	モデルナセラピューティクスインコーポレイテッド	工学操作された核酸の送達および製剤
UA117218C2 (uk)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
EP2763701B1 (fr)	2011-10-03	2018-12-19	Moderna Therapeutics, Inc.	Nucléosides, nucléotides et acides nucléiques modifiés, et leurs utilisations
JP2015504430A (ja) *	2011-11-21	2015-02-12	ノバルティスアーゲー	Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法
AP2014007680A0 (en)	2011-12-02	2014-06-30	Novartis Ag	Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
CA3018046A1 (fr)	2011-12-16	2013-06-20	Moderna Therapeutics, Inc.	Nucleoside, nucleotide, et compositions d'acide nucleique modifies
US9573996B2 (en)	2011-12-16	2017-02-21	Synthon Biopharmaceuticals B.V.	Monoclonal antibodies to human proinflammatory cytokines and methods for treating inflammatory diseases
JP2015508994A (ja)	2011-12-30	2015-03-26	アッヴィ・インコーポレイテッド	Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
WO2013116682A1 (fr)	2012-02-02	2013-08-08	Ensemble Therapeutics Corporation	Composés macrocycliques pour une modulation d'il-17
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en)	2012-04-02	2019-12-10	Modernatx, Inc.	Modified polynucleotides
DE18200782T1 (de)	2012-04-02	2021-10-21	Modernatx, Inc.	Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
CA2868404A1 (fr)	2012-04-05	2013-10-10	F. Hoffmann-La Roche Ag	Anticorps bispecifiques diriges contre tweak humain et l'il17 humaine, et leurs utilisations
CN104244979A (zh)	2012-04-20	2014-12-24	诺华股份有限公司	使用il-17拮抗剂治疗强直性脊柱炎的方法
EP2852615B1 (fr)	2012-05-22	2018-12-05	Bristol-Myers Squibb Company	Anticorps bispécifiques il-17a/f il-23 et leurs utilisations
AR093297A1 (es)	2012-10-31	2015-05-27	Amgen Res (Munich) Gmbh	Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014068029A1 (fr)	2012-10-31	2014-05-08	Takeda Gmbh	Formulation lyophilisée comprenant un composé neutralisant gm-csf
TW202037609A (zh)	2012-11-01	2020-10-16	美商艾伯維有限公司	抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
JP6144355B2 (ja)	2012-11-26	2017-06-07	モデルナティエックスインコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ．	化学修飾ｍＲＮＡ
WO2014107737A2 (fr)	2013-01-07	2014-07-10	Eleven Biotherapeutics, Inc.	Administration locale d'inhibiteurs de l'il-17 en vue du traitement d'affections oculaires
US9193788B2 (en)	2013-02-08	2015-11-24	Novartis Ag	Anti-IL-17A antibodies and their uses
EP2970459A2 (fr)	2013-03-15	2016-01-20	AbbVie Inc.	Protéines de liaison spécifiques à domaines variables doubles dirigées contre il -1beta et il -17
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
WO2014155278A2 (fr) *	2013-03-26	2014-10-02	Novartis Ag	Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'il -17
WO2014161570A1 (fr)	2013-04-03	2014-10-09	Roche Glycart Ag	Anticorps dirigés contre l'il17 humaine et ses utilisations
US9707154B2 (en)	2013-04-24	2017-07-18	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603882B2 (en)	2013-08-13	2017-03-28	Industrial Technology Research Institute	Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
WO2015022656A1 (fr)	2013-08-15	2015-02-19	Novartis Ag	Méthodes de traitement du psoriasis pustuleux généralisé (gpp) au moyen d'antagonistes d'il-17
RU2714919C2 (ru)	2013-08-30	2020-02-21	Такеда Гмбх	Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
WO2015048744A2 (fr)	2013-09-30	2015-04-02	Moderna Therapeutics, Inc.	Polynucléotides codant des polypeptides de modulation immunitaire
BR112016007255A2 (pt)	2013-10-03	2017-09-12	Moderna Therapeutics Inc	polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
CN104936981B (zh) *	2013-11-18	2018-02-27	上海恒瑞医药有限公司	Il‑17a结合物及其用途
CN105916883B (zh) *	2014-01-28	2019-12-03	北京韩美药品有限公司	双功能融合蛋白及其制备方法和用途
TWI713453B (zh)	2014-06-23	2020-12-21	美商健生生物科技公司	干擾素α及ω抗體拮抗劑
US11278618B2 (en) *	2014-09-10	2022-03-22	Novartis Ag	Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
RU2609627C2 (ru) *	2014-09-26	2017-02-02	Закрытое Акционерное Общество "Биокад"	Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
ES2952717T3 (es)	2014-10-14	2023-11-03	Novartis Ag	Moléculas de anticuerpos contra PD-L1 y usos de las mismas
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es)	2014-12-22	2017-04-19	Novartis Ag	Reducción selectiva de residuos de cisteina en anticuerpos il-17
NZ732978A (en)	2015-01-12	2022-01-28	Affibody Ab	Il-17a-binding polypeptides
EP3250927B1 (fr)	2015-01-28	2020-02-19	H. Hoffnabb-La Roche Ag	Marqueurs d'expression génique et traitement de la sclérose en plaques
CN108251431B (zh)	2015-03-05	2020-12-08	北京百特美博生物科技有限公司	双载体系统及其用途
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2017011260A1 (fr)	2015-07-16	2017-01-19	Eli Lilly And Company	Traitement du prurit
US20180340025A1 (en)	2015-07-29	2018-11-29	Novartis Ag	Combination therapies comprising antibody molecules to lag-3
US20180207273A1 (en)	2015-07-29	2018-07-26	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
EP3328418A1 (fr)	2015-07-29	2018-06-06	Novartis AG	Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
WO2017068472A1 (fr)	2015-10-19	2017-04-27	Novartis Ag	Procédés de traitement d'une spondylarthrite axiale non radiographique utilisant des antagonistes d'interleukine -17 (il -17)
US20180371093A1 (en)	2015-12-17	2018-12-27	Novartis Ag	Antibody molecules to pd-1 and uses thereof
EP3426298A4 (fr)	2016-03-10	2019-11-27	Viela Bio, Inc.	Molécules de liaison à l'ilt7 et leurs méthodes d'utilisation
AU2017230091B2 (en)	2016-03-10	2022-04-07	Acceleron Pharma Inc.	Activin type 2 receptor binding proteins and uses thereof
RU2680011C2 (ru)	2016-04-29	2019-02-14	Закрытое Акционерное Общество "Биокад"	Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
FR3051673B1 (fr) *	2016-05-24	2018-06-22	Assistance Publique - Hopitaux De Paris	Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
CN107488227A (zh) *	2016-06-12	2017-12-19	三生国健药业（上海）股份有限公司	抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (fr)	2016-06-22	2017-12-28	Novartis Ag	Méthodes de traitement du vitiligo à l'aide d'anticorps de l'interleukine-17 (il -17)
EP4477265A3 (fr)	2016-07-19	2025-03-19	Novartis AG	Méthodes de traitement du psoriasis de type en plaque nouvelle utilisant des antagonistes de l'il-17
BR112019004990A2 (pt)	2016-09-14	2019-06-04	Beijing hanmi pharm co ltd	anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo
JP2019505516A (ja)	2016-11-28	2019-02-28	ノバルティスアーゲー	インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
JP6995127B2 (ja)	2017-02-10	2022-02-04	ジェネンテック，インコーポレイテッド	抗トリプターゼ抗体、その組成物、及びその使用
WO2018158741A1 (fr)	2017-03-03	2018-09-07	Novartis Ag	Modification de la maladie du psoriasis suite à un traitement à long terme avec un antagoniste de l'il-17
TW201842933A (zh)	2017-05-05	2018-12-16	瑞士商諾華公司	使用il-17拮抗劑選擇性治療氣喘的方法
CN108359011B (zh)	2017-07-21	2019-06-25	华博生物医药技术（上海）有限公司	靶向于白介素17a的抗体、其制备方法和应用
KR20200083996A (ko)	2017-11-02	2020-07-09	노파르티스 아게	인터류킨-17(il-17)을 사용하여 건병증을 치료하는 방법
US20200277369A1 (en)	2017-11-20	2020-09-03	Novartis Ag	Method of treating hidradentitis suppurativa with il-17 antagonists
CA3083949A1 (fr)	2017-11-30	2020-06-06	Novartis Ag	Recepteur d'antigene chimerique ciblant le bcma et ses utilisations
CN112203685A (zh) *	2018-03-29	2021-01-08	瑞美德生物医药科技有限公司	使用结合白细胞介素-17a(il-17a)的抗体的自身免疫紊乱和炎性紊乱的治疗
MY199538A (en)	2018-06-01	2023-11-06	Novartis Ag	Binding molecules against bcma and uses thereof
US12134644B2 (en)	2018-07-31	2024-11-05	Weiqun SHEN	Anti-IL-17A antibodies and use thereof
WO2020064702A1 (fr)	2018-09-25	2020-04-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	Utilisation d'antagonistes de cytokines th17 pour le traitement du remodelage bronchique chez des patients souffrant d'asthme allergique
EP3689907A1 (fr)	2019-01-31	2020-08-05	Numab Therapeutics AG	Anticorps dirigés contre il-17a et leurs procédés d'utilisation
SG11202107995SA (en)	2019-01-31	2021-08-30	Numab Therapeutics AG	Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
SG11202108627SA (en)	2019-02-18	2021-09-29	Lilly Co Eli	Therapeutic antibody formulation
CN110179746A (zh)	2019-05-17	2019-08-30	通化东宝生物科技有限公司	一种稳定的苏金单抗注射剂及其制备方法
AU2020284114A1 (en)	2019-05-31	2022-01-20	Figene, Llc	Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
CN110343666B (zh) *	2019-07-10	2023-05-30	通化东宝药业股份有限公司	一种cho细胞培养的补料培养基及其制备方法和应用
EP4036113A4 (fr)	2019-07-26	2023-01-18	Sinocelltech Ltd.	Anticorps anti-il17a humanisé et son utilisation
EP4006053A4 (fr)	2019-07-30	2022-10-26	Jiangsu Hengrui Medicine Co., Ltd.	Méthode de traitement d'une maladie auto-immune par un antagoniste de l'il-17
US20220363749A1 (en)	2019-09-20	2022-11-17	Novartis Ag	Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists
CN114423455A (zh) *	2019-09-25	2022-04-29	国立大学法人东京大学	用于治疗系统性硬化症的药物组合物
CA3156167A1 (fr)	2019-09-30	2021-04-08	Janssen Pharmaceutica Nv	Compositions et methodes pour un dosage d'entree en prise cible d'il-17 avec des modulateurs a grandes molecules
JP2023502103A (ja)	2019-11-19	2023-01-20	ノバルティスアーゲー	インターロイキン－１７（ｉｌ－１７）アンタゴニストを用いてループス腎炎を治療する方法
CA3162052A1 (fr)	2019-12-06	2021-06-10	Novartis Ag	Procedes de traitement de lichen plan a l'aide d'antagonistes de l'interleukine 17 (il-17)
CN111040035B (zh) *	2019-12-31	2022-05-24	南京融捷康生物科技有限公司	针对il-17ra蛋白的抗体及其制备方法和应用
IL298882A (en)	2020-06-23	2023-02-01	Novartis Ag	Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists
UY39484A (es)	2020-11-02	2022-06-30	Novartis Ag	Inhibidores de interleucina-17
MX2023005353A (es)	2020-11-06	2023-05-22	Novartis Ag	Moleculas de union a cd19 y usos de las mismas.
EP4255927A1 (fr)	2020-12-02	2023-10-11	Fresenius Kabi Deutschland GmbH	Méthodes de réduction sélective d'anticorps
JP2023554489A (ja)	2020-12-22	2023-12-27	ノバルティスアーゲー	細胞培養中の分泌された組換え発現タンパク質中のシステイン残基の酸化レベルを低減するための方法
CN119137115A (zh)	2022-04-25	2024-12-13	诺华股份有限公司	Il-17抑制剂的晶型
WO2023223211A1 (fr)	2022-05-16	2023-11-23	Novartis Ag	Méthodes de traitement de l'artérite à cellules géantes à l'aide d'antagonistes de l'interleukine-17 (il-17)
CN119546340A (zh)	2022-05-18	2025-02-28	诺华股份有限公司	使用白细胞介素-17（il-17）拮抗剂选择性治疗肌腱病的方法
WO2024156841A1 (fr)	2023-01-27	2024-08-02	Fresenius Kabi Deutschland Gmbh	Composition biopharmaceutique
EP4406553A1 (fr)	2023-01-27	2024-07-31	Fresenius Kabi Deutschland GmbH	Composition biopharmaceutique stable de secukinumab
WO2025049345A1 (fr)	2023-08-25	2025-03-06	Proteologix Us Inc.	Constructions d'anticorps multispécifiques anti-il-13 et leurs utilisations
CN117843778B (zh) *	2023-12-21	2024-07-26	北京贝来药业有限公司	针对白介素家族成员的新型纳米抗体及其产品和应用
CN119331085B (zh) *	2024-10-16	2025-03-14	中国科学院合肥物质科学研究院	沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
ATE87659T1 (de)	1986-09-02	1993-04-15	Enzon Lab Inc	Bindungsmolekuele mit einzelpolypeptidkette.
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0463151B1 (fr)	1990-01-12	1996-06-12	Cell Genesys, Inc.	Generation d'anticorps xenogeniques
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de)	1990-08-29	1997-09-15	Genpharm Int	Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US6274711B1 (en)	1993-06-14	2001-08-14	Inserm, Institut National De La Sante Et De La Recherche Medicale	Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en)	1993-06-14	2003-05-13	Schering Corporation	Purified mammalian CTLA-8 antigens and related reagents
PT817847E (pt)	1995-03-23	2005-02-28	Immunex Corp	Receptor de il-17
EP0839196B1 (fr) *	1995-07-19	2005-05-11	Genetics Institute, LLC	Proteines humaines ctla-8 et utilisation de proteines apparentees aux proteines ctla-8
US6074849A (en)	1995-07-19	2000-06-13	Genetics Institute, Inc.	Polynucleotides encoding human CTLA-8 related proteins
JP3253633B2 (ja)	1995-10-27	2002-02-04	シェーリングコーポレイション	哺乳動物ｃｔｌａ−８および関連薬剤の新規使用
WO1998023284A1 (fr)	1996-11-27	1998-06-04	Immunex Corporation	Procede permettant de reguler la production de monoxyde d'azote
US6849719B2 (en)	1997-09-17	2005-02-01	Human Genome Sciences, Inc.	Antibody to an IL-17 receptor like protein
US6482923B1 (en)	1997-09-17	2002-11-19	Human Genome Sciences, Inc.	Interleukin 17-like receptor protein
DE69841140D1 (de)	1997-09-17	2009-10-22	Human Genome Sciences Inc	Interleukin-17 rezeptor-ähnliches protein
JP4620243B2 (ja)	1997-11-10	2011-01-26	サイティミューンサイエンシーズ，インコーポレイテッド	生物学的に活性な因子の標的化された送達のための組成物および方法
US6562578B1 (en)	1999-01-11	2003-05-13	Schering Corporation	IL-17-like cytokine binding compounds and antibodies
WO1999032632A1 (fr)	1997-12-19	1999-07-01	Millennium Pharmaceuticals, Inc.	Nouvelles molecules d'un facteur apparente a l'interleukine issu d'un embryon (edirf) et leurs utilisations
AU2031399A (en)	1998-01-09	1999-07-26	Immunex Corporation	Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
JP2003502006A (ja)	1998-01-09	2003-01-21	イミュネックス・コーポレーション	Ｉｌ−１７ｒｈｄｎａ及びポリペプチド
AU3291099A (en)	1998-02-11	1999-08-30	Maxygen, Inc.	Genetic vaccine vector engineering
CA2328496C (fr)	1998-05-15	2016-01-05	Genentech, Inc.	Polypeptides homologues de il-17 et utilisations therapeutiques de ceux-ci
ES2300154T3 (es)	1998-09-17	2008-06-01	Zymogenetics, Inc.	Factor de crecimiento de transformacion beta-9 en mamiferos (ztgfss9).
WO2000020593A1 (fr)	1998-10-02	2000-04-13	Eli Lilly And Company	Acides nucleiques, polypeptides, vecteurs, cellules hotes homologues de l'il-17, leurs procedes de production et leurs utilisations
JP2000186046A (ja) *	1998-10-14	2000-07-04	Snow Brand Milk Prod Co Ltd	慢性関節リウマチ治療剤及び診断方法
WO2000022909A2 (fr)	1998-10-19	2000-04-27	Biotech Australia Pty. Limited	Systemes d'administration orale
DE29820466U1 (de)	1998-11-16	1999-04-08	Reutter, Werner, Prof. Dr.med., 14195 Berlin	Rekombinante Glycoproteine und sie enthaltende Arzneimittel
US6734172B2 (en)	1998-11-18	2004-05-11	Pacific Northwest Research Institute	Surface receptor antigen vaccines
WO2000042187A1 (fr)	1999-01-11	2000-07-20	Schering Corporation	Cytokines de mammifere liees a l'interleukine-17 (il-171), polynucleotides les codant et leurs utilisations
KR20010089764A (ko)	1999-01-11	2001-10-08	둘락 노먼 씨.	인터류킨-17과 관련된 포유류의 사이토카인, 이를코딩하는 폴리뉴클레오티드 및 이의 용도
ATE216875T1 (de)	1999-01-27	2002-05-15	Idea Ag	Nichtinvasive impfung durch die haut
ATE412433T1 (de)	1999-02-12	2008-11-15	Scripps Research Inst	Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
EP1053751A1 (fr)	1999-05-17	2000-11-22	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Compositions et méthodes pour le traitement des désordres de la prolifération cellulaire
US6036128A (en)	1999-05-17	2000-03-14	Common Ground Recycling, Inc.	Tire shredding machine and method of using the same
WO2001015728A1 (fr)	1999-08-27	2001-03-08	University Health Network	Procede d'activation de lymphocytes t cytotoxiques (ctls) in vivo: composition comprenant un anticorps anti cd40 (ou cd40l ou une proteine liant le cd40) et un antigene
JP2001086046A (ja) *	1999-09-09	2001-03-30	Nec Corp	カメラ付き携帯電話装置
US7220840B2 (en)	2000-06-16	2007-05-22	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator protein
EP1294769B1 (fr)	2000-06-16	2011-01-05	Human Genome Sciences, Inc.	Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b
WO2002033083A2 (fr)	2000-10-13	2002-04-25	Eli Lilly And Company	Procedes relatifs a l'utilisation de polypeptide lie a l'interleukine 17 (il-17) humaine pour le traitement de maladies-
CA2425506A1 (fr)	2000-10-18	2002-08-01	Immunex Corporation	Methodes de traitement de la polyarthrite rhumatoide a l'aide d'antagonistes de l'il-17
ES2360481T3 (es)	2001-01-25	2011-06-06	Zymogenetics, Inc.	Procedimiento para tratar psoriasis usando un antagonista de il- 17d.
EP2009027B1 (fr) *	2001-04-27	2014-05-21	Kyowa Hakko Kirin Co., Ltd.	Anticorps monoclonal anti-CD40
EP1456347A4 (fr)	2001-11-16	2006-08-02	Human Genome Sciences Inc	Anticorps se liant a blys selon un mode immunospecifique
PL376536A1 (pl)	2002-08-28	2006-01-09	Immunex Corporation	Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego
CA2526398C (fr) *	2003-05-21	2014-07-15	Medarex, Inc.	Anticorps monoclonaux humains diriges contre l'antigene protecteur de bacillus anthracis
PL1983000T3 (pl)	2003-11-21	2016-02-29	Ucb Biopharma Sprl	Sposób leczenia stwardnienia rozsianego przez hamowanie aktywności IL-17
EP1761643A1 (fr) *	2004-05-03	2007-03-14	Schering Corporation	Utilisation de l'expression d'il-17 pour predire une inflammation cutanee et methodes de traitement
GB0417487D0 (en) *	2004-08-05	2004-09-08	Novartis Ag	Organic compound
DE602006009834D1 (de)	2005-09-01	2009-11-26	Schering Corp	Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung

2004
- 2004-08-05 GB GBGB0417487.6A patent/GB0417487D0/en not_active Ceased
2005
- 2005-08-03 PE PE2005000902A patent/PE20060418A1/es active IP Right Grant
- 2005-08-04 EP EP15156029.9A patent/EP2902039B1/fr active Active
- 2005-08-04 ES ES10174725.1T patent/ES2536228T3/es active Active
- 2005-08-04 BR BR122018075556-3A patent/BR122018075556B1/pt active IP Right Grant
- 2005-08-04 CN CN2005800265694A patent/CN101001645B/zh active Active
- 2005-08-04 RU RU2007108067A patent/RU2426741C3/ru active
- 2005-08-04 SI SI200532208T patent/SI2902039T1/en unknown
- 2005-08-04 HU HUE10174725A patent/HUE025815T2/en unknown
- 2005-08-04 EP EP05770286.2A patent/EP1776142B9/fr active Active
- 2005-08-04 WO PCT/EP2005/008470 patent/WO2006013107A1/fr active Application Filing
- 2005-08-04 NZ NZ552658A patent/NZ552658A/en unknown
- 2005-08-04 KR KR1020077002745A patent/KR100852523B1/ko active Active
- 2005-08-04 SG SG200905203-6A patent/SG155186A1/en unknown
- 2005-08-04 US US11/658,344 patent/US7807155B2/en active Active
- 2005-08-04 PT PT101751501T patent/PT2364729E/pt unknown
- 2005-08-04 PL PL15156029T patent/PL2902039T3/pl unknown
- 2005-08-04 CA CA2573586A patent/CA2573586C/fr active Active
- 2005-08-04 SI SI200531965T patent/SI2366405T1/sl unknown
- 2005-08-04 DK DK10174725.1T patent/DK2366405T3/en active
- 2005-08-04 BR BR122017009404-1A patent/BR122017009404B1/pt active IP Right Grant
- 2005-08-04 PL PL05770286T patent/PL1776142T4/pl unknown
- 2005-08-04 SI SI200531869T patent/SI2364729T1/sl unknown
- 2005-08-04 DK DK10175150.1T patent/DK2364729T6/en active
- 2005-08-04 DK DK05770286.2T patent/DK1776142T6/en active
- 2005-08-04 JP JP2007524286A patent/JP4682200B2/ja active Active
- 2005-08-04 AR ARP050103256A patent/AR050200A1/es active IP Right Grant
- 2005-08-04 ES ES05770286.2T patent/ES2367440T7/es active Active
- 2005-08-04 PT PT05770286T patent/PT1776142E/pt unknown
- 2005-08-04 TW TW094126471A patent/TWI359153B/zh active
- 2005-08-04 PL PL10174725T patent/PL2366405T3/pl unknown
- 2005-08-04 SI SI200531390T patent/SI1776142T1/sl unknown
- 2005-08-04 HU HUE15156029A patent/HUE038187T2/hu unknown
- 2005-08-04 PL PL10175150T patent/PL2364729T6/pl unknown
- 2005-08-04 EP EP18166164.6A patent/EP3409288A1/fr not_active Withdrawn
- 2005-08-04 LT LTEP15156029.9T patent/LT2902039T/lt unknown
- 2005-08-04 PT PT101747251T patent/PT2366405E/pt unknown
- 2005-08-04 PT PT151560299T patent/PT2902039T/pt unknown
- 2005-08-04 ES ES10175150.1T patent/ES2487533T7/es active Active
- 2005-08-04 BR BRPI0513078A patent/BRPI0513078C1/pt active IP Right Grant
- 2005-08-04 DK DK15156029.9T patent/DK2902039T3/en active
- 2005-08-04 EP EP10174725.1A patent/EP2366405B1/fr active Active
- 2005-08-04 KR KR1020087006406A patent/KR20080029018A/ko not_active Withdrawn
- 2005-08-04 EP EP10175150.1A patent/EP2364729B3/fr active Active
- 2005-08-04 AT AT05770286T patent/ATE517924T1/de active
- 2005-08-04 ES ES15156029.9T patent/ES2677245T3/es active Active
- 2005-08-04 AU AU2005268857A patent/AU2005268857C1/en active Active
- 2005-08-04 MY MYPI20053629A patent/MY144925A/en unknown
- 2005-08-04 MX MX2007001338A patent/MX2007001338A/es active IP Right Grant
- 2005-08-04 TR TR2018/08057T patent/TR201808057T4/tr unknown
2007
- 2007-01-09 ZA ZA200700242A patent/ZA200700242B/xx unknown
- 2007-01-15 IL IL180717A patent/IL180717A/en active Protection Beyond IP Right Term
- 2007-01-25 EC EC2007007198A patent/ECSP077198A/es unknown
- 2007-02-02 TN TNP2007000034A patent/TNSN07034A1/en unknown
- 2007-02-20 NO NO20070985A patent/NO336279B1/no active Protection Beyond IP Right Term
- 2007-02-22 MA MA29710A patent/MA28982B1/fr unknown
- 2007-08-23 HK HK07109203.7A patent/HK1101277A1/xx unknown
2010
- 2010-02-18 US US12/707,934 patent/US8119131B2/en active Active
- 2010-04-28 AU AU2010201689A patent/AU2010201689B2/en active Active
2011
- 2011-04-06 RU RU2011113153/10A patent/RU2011113153A/ru not_active Application Discontinuation
- 2011-09-27 CY CY20111100936T patent/CY1111963T1/el unknown
- 2011-10-19 HR HRP20110758TT patent/HRP20110758T4/hr unknown
2012
- 2012-01-13 US US13/349,689 patent/US8617552B2/en active Active
2013
- 2013-11-20 US US14/085,074 patent/US20140079719A1/en not_active Abandoned
2014
- 2014-08-08 CY CY20141100628T patent/CY1115444T1/el unknown
2015
- 2015-01-13 NO NO20150064A patent/NO337286B1/no active Protection Beyond IP Right Term
- 2015-01-13 NO NO20150065A patent/NO337129B1/no unknown
- 2015-02-18 US US14/625,073 patent/US9765140B2/en active Active
- 2015-05-04 HR HRP20150480TT patent/HRP20150480T1/hr unknown
- 2015-05-07 CY CY20151100401T patent/CY1116256T1/el unknown
- 2015-07-03 FR FR15C0048C patent/FR15C0048I2/fr active Active
- 2015-07-07 BE BE2015C041C patent/BE2015C041I2/nl unknown
- 2015-07-09 NL NL300749C patent/NL300749I2/nl unknown
- 2015-07-09 HU HUS1500037C patent/HUS1500037I1/hu unknown
- 2015-07-10 CY CY2015030C patent/CY2015030I2/el unknown
- 2015-07-10 LT LTPA2015029C patent/LTPA2015029I1/lt unknown
- 2015-07-10 LU LU92768C patent/LU92768I2/fr unknown
- 2015-08-21 HK HK15108118.3A patent/HK1207559A1/xx unknown
- 2015-10-26 NO NO2015023C patent/NO2015023I1/no not_active IP Right Cessation
- 2015-12-23 NO NO20151787A patent/NO341384B1/no active Protection Beyond IP Right Term
2016
- 2016-08-23 NO NO2016017C patent/NO2016017I1/no unknown
2017
- 2017-08-11 US US15/674,970 patent/US10344084B2/en active Active
- 2017-10-24 NO NO20171697A patent/NO348010B1/no unknown
2018
- 2018-02-14 NO NO2018007C patent/NO2018007I1/no unknown
- 2018-07-06 HR HRP20181069TT patent/HRP20181069T1/hr unknown
- 2018-07-11 CY CY181100727T patent/CY1120723T1/el unknown
- 2018-10-10 LT LTPA2018515C patent/LTPA2018515I1/lt unknown
- 2018-10-10 HU HUS1800040C patent/HUS1800040I1/hu unknown
- 2018-10-10 CY CY2018027C patent/CY2018027I1/el unknown
- 2018-10-10 LU LU00088C patent/LUC00088I2/en unknown
- 2018-12-10 HK HK18115774.0A patent/HK1256639A1/zh unknown
2019
- 2019-05-15 US US16/412,543 patent/US20190270804A1/en not_active Abandoned
2022
- 2022-06-24 NO NO2022026C patent/NO2022026I1/no unknown
- 2022-07-07 US US17/859,653 patent/US20230235038A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SI1776142T1 (sl)	2011-11-30
PL2902039T3 (pl)	2018-09-28
HK1207559A1 (en)	2016-02-05
CA2573586C (fr)	2013-06-25
US20150152178A1 (en)	2015-06-04
HUS1800040I1 (hu)	2018-11-28
US20100215666A1 (en)	2010-08-26
EP1776142B9 (fr)	2016-09-07
ES2367440T9 (es)	2021-04-28
EP2364729A2 (fr)	2011-09-14
LU92768I2 (fr)	2015-11-03
CY2015030I2 (el)	2017-11-14
NO2015023I2 (no)	2015-10-26
AR050200A1 (es)	2006-10-04
SI2366405T1 (sl)	2015-07-31
CY1120723T1 (el)	2019-12-11
EP1776142B1 (fr)	2011-07-27
CY2018027I2 (el)	2020-05-29
NO348010B1 (no)	2024-06-17
EP3409288A1 (fr)	2018-12-05
US7807155B2 (en)	2010-10-05
EP1776142A1 (fr)	2007-04-25
NO2016017I1 (no)	2016-08-23
ES2367440T3 (es)	2011-11-03
CY1116256T1 (el)	2017-02-08
CA2573586A1 (fr)	2006-02-09
EP2364729B1 (fr)	2014-05-14
HRP20110758T4 (hr)	2015-07-31
PT2366405E (pt)	2015-06-30
ZA200700242B (en)	2008-08-27
US20170355762A1 (en)	2017-12-14
US9765140B2 (en)	2017-09-19
NO2015023I1 (no)	2015-11-02
EP2902039A1 (fr)	2015-08-05
SG155186A1 (en)	2009-09-30
AU2005268857A1 (en)	2006-02-09
PT1776142E (pt)	2011-10-06
JP4682200B2 (ja)	2011-05-11
NO341384B1 (no)	2017-10-30
KR100852523B1 (ko)	2008-08-14
BE2015C041I2 (fr)	2024-10-08
CY2015030I1 (el)	2015-11-04
TR201808057T4 (tr)	2018-06-21
LUC00088I2 (fr)	2018-12-17
NO20070985L (no)	2007-03-30
NO336279B1 (no)	2015-07-06
LTC1776142I2 (lt)	2022-07-11
PL1776142T3 (pl)	2011-12-30
PT2902039T (pt)	2018-07-17
ECSP077198A (es)	2007-02-28
BRPI0513078A (pt)	2008-04-22
HUE025815T2 (en)	2016-04-28
US10344084B2 (en)	2019-07-09
RU2426741C3 (ru)	2017-11-15
EP1776142B3 (fr)	2015-06-24
ES2536228T3 (es)	2015-05-21
LTPA2018515I1 (lt)	2018-10-25
AU2005268857B2 (en)	2010-01-28
DK2364729T3 (da)	2014-07-21
GB0417487D0 (en)	2004-09-08
DK1776142T3 (da)	2011-10-31
US20230235038A1 (en)	2023-07-27
CY1115444T1 (el)	2017-01-04
AU2010201689B2 (en)	2011-09-29
BRPI0513078B8 (pt)	2019-08-27
SI2364729T1 (sl)	2014-08-29
CN101001645B (zh)	2012-09-05
NO20150065L (no)	2007-03-30
NO20150064L (no)	2007-03-30
NO2018007I1 (no)	2018-02-14
AU2005268857C1 (en)	2012-01-19
BR122017009404B1 (pt)	2022-02-22
PL2364729T3 (pl)	2014-10-31
US8119131B2 (en)	2012-02-21
ES2677245T3 (es)	2018-07-31
PL1776142T4 (pl)	2018-04-30
PL2364729T6 (pl)	2016-06-30
NO337286B1 (no)	2016-02-29
NO20171697A1 (no)	2007-03-30
BR122018075556B1 (pt)	2022-10-18
TNSN07034A1 (en)	2008-06-02
ES2367440T7 (es)	2015-07-14
AU2005268857B8 (en)	2010-05-27
IL180717A (en)	2012-07-31
WO2006013107A1 (fr)	2006-02-09
LTPA2015029I1 (lt)	2022-07-11
HK1256639A1 (zh)	2019-09-27
NZ552658A (en)	2009-11-27
CY1111963T1 (el)	2015-11-04
ES2487533T3 (es)	2014-08-21
MX2007001338A (es)	2008-03-11
US20190270804A1 (en)	2019-09-05
SI2902039T1 (en)	2018-07-31
IL180717A0 (en)	2007-06-03
NO2022026I1 (no)	2022-06-24
RU2007108067A (ru)	2008-09-10
ES2487533T7 (es)	2015-07-14
TW200617025A (en)	2006-06-01
HRP20181069T1 (hr)	2018-09-07
EP2366405A3 (fr)	2012-01-18
PT2364729E (pt)	2014-09-01
MY144925A (en)	2011-11-30
NO20151787L (no)	2006-02-06
US8617552B2 (en)	2013-12-31
EP2364729B3 (fr)	2015-06-24
KR20070036166A (ko)	2007-04-02
KR100852523B9 (ko)	2025-03-28
US20140079719A1 (en)	2014-03-20
RU2426741C2 (ru)	2011-08-20
MA28982B1 (fr)	2007-11-01
JP2008507988A (ja)	2008-03-21
LT2902039T (lt)	2018-06-25
US20090280131A1 (en)	2009-11-12
PL2366405T3 (pl)	2015-08-31
ATE517924T1 (de)	2011-08-15
PE20060418A1 (es)	2006-06-15
BRPI0513078B1 (pt)	2019-02-19
KR20080029018A (ko)	2008-04-02
NL300749I2 (nl)	2017-11-02
AU2010201689A1 (en)	2010-05-20
DK2364729T6 (en)	2015-07-06
FR15C0048I2 (fr)	2015-11-20
HUS1500037I1 (hu)	2017-10-30
HK1101277A1 (en)	2007-10-12
TWI359153B (en)	2012-03-01
DK1776142T6 (en)	2015-07-06
CY2018027I1 (el)	2020-05-29
US20120107325A1 (en)	2012-05-03
HRP20150480T1 (hr)	2015-07-17
CN101001645A (zh)	2007-07-18
HRP20110758T1 (en)	2011-11-30
DK2366405T3 (en)	2015-05-11
PL1776142T6 (pl)	2016-06-30
DK2902039T3 (en)	2018-07-16
RU2011113153A (ru)	2012-10-20
EP2364729A3 (fr)	2012-01-18
BRPI0513078C1 (pt)	2021-05-25
EP2366405A2 (fr)	2011-09-21
NO337129B1 (no)	2016-01-25
EP2902039B1 (fr)	2018-04-11
EP2366405B1 (fr)	2015-02-25
HUE038187T2 (hu)	2018-10-29

Publication	Publication Date	Title
FR15C0048I2 (fr)	2015-11-20	Anticorps antagonistes de il-17
EP1964852A4 (fr)	2010-02-24	Anticorps anti-ilt7
CY2016030I2 (el)	2016-12-14	Αντισωματα εναντι της il-17
NO20071430L (no)	2007-05-15	Anti-OX4OL antistoffer
EP2076614A4 (fr)	2012-07-04	Anticorps synthetiques
EP2011869A4 (fr)	2010-03-17	Nouvel anticorps anti-cd98
EP2006379A4 (fr)	2010-06-30	Anticorps bispecifique hautement fonctionnel
EP1850873A4 (fr)	2012-06-13	Anticorps anti-tgf-beta
EP1810979A4 (fr)	2008-12-24	ANTICORPS IgGG4 HUMAINS STABILISES
MA29014B1 (fr)	2007-11-01	Formulations d'anticorps
EP1940466A4 (fr)	2010-04-07	Anticorps monoclonal anti-addl et leur utilisation
EP1761566A4 (fr)	2008-10-29	Anticorps monoclonaux humanises anti-tag-72
DE602005012636D1 (de)	2009-03-19	Erung
EP1937814A4 (fr)	2010-05-05	Anticorps protéiques anti-apoptotiques
EP1910828A4 (fr)	2012-03-14	Anticorps des récepteurs de chimiokines phosphospécifiques
EP1761562A4 (fr)	2009-03-25	Anticorps specifiques de conformation
EP1826218A4 (fr)	2009-11-25	Anticorps anti-baff humain
DK1809660T3 (da)	2014-10-20	Thymus-specifikt protein
EP1646401A4 (fr)	2007-07-18	Anticorps humains specifiques
EP1817575A4 (fr)	2016-05-11	Goniometre
FR2880112B1 (fr)	2007-02-09	Pese-personne
FR2877833B1 (fr)	2007-10-12	Correcteur de lordoses
FI20041385L (fi)	2006-04-28	Symmetria-akselin määrittäminen
DE112005003066A5 (de)	2007-09-13	Geodätisches Gerät
DE602005013453D1 (de)	2009-05-07	Drosselklappe